Latest News

(UroToday.com) The treatment landscape for first-line therapy among patients with metastatic renal cell carcinoma (mRCC) has changed dramatically over the past 2 years. In 2018, publication of the CheckMate214 data demonstrated a survival benefit for patients treated with nivolumab and ipilimumab compared with sunitinib in intermediate and poor-risk mRCC, ushering in the immunotherapy era for mRCC. […]

(UroToday.com) The treatment landscape for first-line therapy among patients with metastatic renal cell carcinoma (mRCC) has changed dramatically over the past 2 years. In 2018, publication of the CheckMate214 data demonstrated a survival benefit for patients treated with nivolumab and ipilimumab compared with sunitinib in intermediate and poor-risk mRCC, ushering in the immunotherapy era for mRCC. […]

(UroToday.com) There has been a rapid evolution in treatment options for patients with non-metastatic castration-resistant prostate cancer (nmCRPC) since the spring of 2018. Up until the presentation of SPARTAN and PROSPER trials, reporting on the use of apalutamide and enzalutamide in non-metastatic castration-resistant prostate cancer, at GU ASCO in February 2018, there were no specifically approved […]

(UroToday.com) Treatment paradigms for patients with metastatic hormone-sensitive prostate cancer (mHSPC) have changed dramatically in the past 4 years. Before 2016, there were no agents with a demonstrated overall survival benefit in this disease space. As a result, for nearly 20 years, there was no appreciable improvement in survival for men diagnosed with mHSPC. However, […]

(UroToday.com) There has been a rapid evolution in treatment options for patients with non-metastatic castration-resistant prostate cancer (nmCRPC) since the spring of 2018. Up until the presentation of SPARTAN and PROSPER trials, reporting on the use of apalutamide and enzalutamide in non-metastatic castration-resistant prostate cancer, at GU ASCO in February 2018, there were no specifically approved […]

(UroToday.com) Treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) have rapidly evolved over the past 15 years. In 2004, Dr. Tannock reported results of the TX-327 trial which demonstrated improved overall survival for patients with mCRPC who received docetaxel, the first such evidence supporting life prolonging therapy in this disease space. Since then, a […]

Background While there have been dramatic changes in treatment options for patients with advanced prostate cancer over the past 5 years, perhaps the greatest change has been for patients with non-metastatic castration-resistant prostate cancer (nmCRPC). Prior to February 14, 2018, there were no agents approved by the United States Food and Drug Administration (FDA) for […]

Key Study to be Presented at ESMO Virtual Congress 2020 Shows Nearly Half of Patients Receiving Immunotherapy are Unaware of Possible Financial Toxicity (FT) Research Demonstrates Importance of Engaging Patients Throughout the Cancer Journey, Suggests Physicians Discuss FT from Moment of Diagnosis San Francisco, CA (UroToday.com) — Belong.Life (Belong), a developer of social and professional networks for […]

More than 50% of patients treated with Opdivo plus Yervoy were alive at four years Patients who received Opdivo plus Yervoy maintained durable responses, with the combination showing improved duration of response vs. sunitinib Updated results from the Phase 3 CheckMate -214 trial, presented at the European Society for Medical Oncology Virtual Congress 2020, represent longest follow-up by nearly two years of any […]

Spain has been one of the most affected countries by the COVID-19 pandemic, being among the countries with worse numbers, including the death rate. However, most patients are asymptomatic, although they are very contagious.